Tweet IRVINE, CA, Clinical-stage biopharmaceutical company, today announced the completion of $60 million in Series B financing, led by Vivo Capital.
To export Tarsus Pharmaceuticals funding data to PDF and Excel, clickClick here for more funding data on Tarsus PharmaceuticalsTo export Tarsus Pharmaceuticals funding data to PDF and Excel, click here Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the completion of $60 million in Series B financing.
The financing was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, and Horowitz Group.
Michael Ackermann, PhD, Tarsus Chairman, commented, "We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine."
Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care. | To read full story, visit https://startuparound.com/read/1578522607.2109778/Tarsus-Pharmaceuticals-Raises-$60M-in-Series-B?ref=audio_experience